{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:30:53Z","timestamp":1777991453616,"version":"3.51.4"},"reference-count":252,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Women's Dermatology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijwd.2019.10.003","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T16:28:26Z","timestamp":1573144106000},"page":"285-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Dermatologic conditions in women receiving systemic cancer therapy"],"prefix":"10.1097","volume":"5","author":[{"given":"Michelle N.","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6383-9837","authenticated-orcid":false,"given":"Julie Y.","family":"Ramseier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3757-8477","authenticated-orcid":false,"given":"Jonathan S.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1634\/theoncologist.2011-0243","article-title":"Chemotherapy and fingerprint loss: beyond cosmetic","volume":"17","author":"Al-Ahwal","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000093005","article-title":"Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer","volume":"70","author":"Al-Batran","year":"2006","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D31N2774JC","article-title":"Persistent hair growth during treatment with the EGFR inhibitor erlotinib","volume":"15","author":"Alexandrescu","year":"2009","journal-title":"Dermatol Online J"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/13697137.2011.608596","article-title":"Menopausal hot flushes and night sweats: Where are we now?","volume":"14","author":"Archer","year":"2011","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2010.06.051","article-title":"The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies","volume":"65","author":"Balagula","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"10.1016\/j.ijwd.2019.10.003_b0030","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2009.26.6379","article-title":"Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9","volume":"28","author":"Barton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2010.08.035","article-title":"Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer","volume":"204","author":"Baumgart","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ced.12694","article-title":"Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis","volume":"41","author":"Belum","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0045","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","article-title":"Alopecia in patients treated with molecularly targeted anticancer therapies","volume":"26","author":"Belum","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0050","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaad.2017.03.039","article-title":"A prospective, randomized, double-blinded, split-face\/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash","volume":"77","author":"Belum","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0055","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1684\/ejd.2013.2048","article-title":"The impact of nail disorders on quality of life","volume":"23","author":"Belyayeva","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamadermatol.2017.0500","article-title":"Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors","volume":"153","author":"B\u00e9trian","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3\u20134","key":"10.1016\/j.ijwd.2019.10.003_b0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/pon.3819","article-title":"Sexual functioning in breast cancer survivors experiencing body image disturbance","volume":"25","author":"Boquiren","year":"2016","journal-title":"Psychooncology"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/archdermatol.2011.3482","article-title":"Topical psoralen plus UV-A therapy for tyrosine kinase inhibitor-induced hand-foot syndrome","volume":"148","author":"Bos","year":"2012","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0080","first-page":"759","article-title":"Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study","volume":"16","author":"Bozkurt Duman","year":"2011","journal-title":"J Balk Union Oncol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.12788\/jcso.0017","article-title":"Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy","volume":"12","author":"Braik","year":"2014","journal-title":"J Community Support Oncol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002820-200601000-00006","article-title":"Postmenopausal women with breast cancer: their experiences of the chemotherapy treatment period","volume":"29","author":"Browall","year":"2006","journal-title":"Cancer Nurs"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b0100","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00520-018-4054-z","article-title":"Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer","volume":"26","author":"Bun","year":"2018","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0105","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1037\/0022-006X.59.4.518","article-title":"Preparing patients for cancer chemotherapy: effect of coping preparation and relaxation interventions","volume":"59","author":"Burish","year":"1991","journal-title":"J Consult Clin Psychol"},{"issue":"14","key":"10.1016\/j.ijwd.2019.10.003_b0110","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0115","article-title":"NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7","author":"Burtness","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0120","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejon.2011.06.007","article-title":"Taxane-induced nail changes: predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity","volume":"16","author":"Can","year":"2012","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejon.2012.06.003","article-title":"A comparison of men and women\u2019s experiences of chemotherapy-induced alopecia","volume":"17","author":"Can","year":"2013","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.ijwd.2019.10.003_b0135","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-019-00825-0","article-title":"A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia","author":"Capriotti","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ijwd.2019.10.003_b0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/CMAR.S139301","article-title":"Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases","volume":"9","author":"Capriotti","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b9050","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjd.13743","article-title":"The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis","volume":"173","author":"Capriotti","year":"2015","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b0145","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/1060028014543099","article-title":"New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene\/conjugated estrogens and paroxetine mesylate","volume":"48","author":"Carris","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1743-7563.2010.01311.x","article-title":"Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia","volume":"6","author":"Chalermchai","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ijwd.2019.10.003_b0155","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.breast.2016.02.013","article-title":"Hot flashes in breast cancer survivors: frequency, severity and impact","volume":"27","author":"Chang","year":"2016","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0165","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.20878","article-title":"Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma","volume":"103","author":"Chansky","year":"2005","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ijwd.2019.10.003_b0170","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMicm1409635","article-title":"Loss of fingerprints","volume":"372","author":"Chavarri-Guerra","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0175","first-page":"e201","article-title":"Treatment of oral mucositis due to chemotherapy","volume":"8","author":"Chaveli-L\u00f3pez","year":"2016","journal-title":"J Clin Exp Dent"},{"issue":"8","key":"10.1016\/j.ijwd.2019.10.003_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072245","article-title":"Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b9000","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejon.2006.03.004","article-title":"Oral mucositis and quality of life of Hong Kong Chinese patients with cancer therapy","volume":"11","author":"Cheng","year":"2007","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0185","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2012.12.959","article-title":"\u201cArrow\u201d sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors","volume":"69","author":"Cheng","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0190","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/j.1365-4632.2011.05422.x","article-title":"Erlotinib-induced hair repigmentation","volume":"53","author":"Cheng","year":"2014","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2013.05.032","article-title":"Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions","volume":"69","author":"Chiang","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b0200","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pon.3531","article-title":"Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients","volume":"23","author":"Choi","year":"2014","journal-title":"Psychooncology"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0205","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol (Madr)"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0210","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00520-015-2781-y","article-title":"Xerosis and pruritus as major EGFRI-associated adverse events","volume":"24","author":"Clabbers","year":"2016","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0215","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc.2016.30","article-title":"Sexual dimorphism in cancer","volume":"16","author":"Clocchiatti","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0220","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b0225","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0235","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.2012.318","article-title":"A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications","volume":"107","author":"Corrie","year":"2012","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/jamadermatol.2017.4120","article-title":"Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine","volume":"154","author":"Cubir\u00f3","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0245","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis","volume":"77","author":"Dai","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ijwd.2019.10.003_b0255","first-page":"652","article-title":"The hand-foot-syndrome associated with medical tumor therapy-classification and management","volume":"9","author":"Degen","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0260","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jdcr.2017.03.017","article-title":"Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol","volume":"3","author":"Demirkan","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1515\/bjdm-2015-0045","article-title":"Oral ulceration due to methotrexate treatment: A report of 3 cases and literature review","volume":"19","author":"Dervisoglou","year":"2015","journal-title":"Balk J Dent Med"},{"issue":"11","key":"10.1016\/j.ijwd.2019.10.003_b0270","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archderm.144.11.1524","article-title":"Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib","volume":"144","author":"Donovan","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0275","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrc.2015.09.003","article-title":"Drug induced periarticular thenar erythema with onycholysis related to nano-albumin bound paclitaxel therapy","volume":"4","author":"Dow","year":"2015","journal-title":"Cancer Treat Commun"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0285","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","article-title":"Oral dexamethasone attenuates Doxil\u00ae-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies","volume":"94","author":"Drake","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijwd.2019.10.003_b0290","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","article-title":"Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib","volume":"23","author":"Dranitsaris","year":"2012","journal-title":"Ann Oncol"},{"issue":"33","key":"10.1016\/j.ijwd.2019.10.003_b0295","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2012.41.8525","article-title":"Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial","volume":"30","author":"Duijts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0300","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","article-title":"A randomized trial of minoxidil in chemotherapy-induced alopecia","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0310","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0315","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.ijrobp.2007.01.053","article-title":"Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies","volume":"68","author":"Elting","year":"2007","journal-title":"Int J Radiat Oncol"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b0320","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00520-017-3623-x","article-title":"Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash","volume":"25","author":"Eriksen","year":"2017","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0325","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00280-007-0650-1","article-title":"Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation","volume":"62","author":"Fabi","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0330","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0335","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-016-0517-x","article-title":"Vaginal health during breast cancer treatment","volume":"18","author":"Falk","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0345","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12905-018-0550-z","article-title":"MENOS4 trial: a multicentre randomised controlled trial (RCT) of a breast care nurse delivered cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flushes in women with breast cancer: study protocol","volume":"18","author":"Fenlon","year":"2018","journal-title":"BMC Womens Health"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0350","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0355","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0360","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2010.2016","article-title":"Efficacy of escitalopram for hot flashes in healthy menopausal women","volume":"305","author":"Freeman","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0365","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2018.5071","article-title":"Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia","volume":"155","author":"Freites-Martinez","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0370","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Freites-Martinez","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0375","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","article-title":"Hair disorders in patients with cancer","volume":"80","author":"Freites-Martinez","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.ijwd.2019.10.003_b0380","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00520-009-0769-1","article-title":"Unanticipated toxicities from anticancer therapies: survivors\u2019 perspectives","volume":"18","author":"Gandhi","year":"2010","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0385","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0390","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/bjd.13443","article-title":"Long-term safety and efficacy of bimatoprost solution 0\u00b703% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial","volume":"172","author":"Glaser","year":"2015","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.ijwd.2019.10.003_b0395","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer","volume":"16","author":"Gomez","year":"2011","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0400","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0405","first-page":"129","article-title":"The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies","volume":"12","author":"Granai","year":"1991","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0410","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00520-012-1715-1","article-title":"Pre-emptive skin toxicity treatment for anti-EGFR drugs: Evaluation of efficacy of skin moisturizers and lymecycline. A phase II study","volume":"21","author":"Grande","year":"2013","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0415","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1078155206069242","article-title":"Management of hand-foot syndrome induced by capecitabine","volume":"12","author":"Gressett","year":"2006","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0420","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40487-017-0050-6","article-title":"EGFR inhibitors and cutaneous complications: a practical approach to management","volume":"5","author":"Guggina","year":"2017","journal-title":"Oncol Ther"},{"key":"10.1016\/j.ijwd.2019.10.003_b0425","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clindermatol.2011.11.010","article-title":"Evaluation of cutaneous body image dissatisfaction in the dermatology patient","volume":"31","author":"Gupta","year":"2013","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0430","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13697130500487224","article-title":"Menopausal symptoms in women treated for breast cancer: The prevalence and severity of symptoms and their perceived effects on quality of life","volume":"9","author":"Gupta","year":"2006","journal-title":"Climacteric"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0435","first-page":"457","article-title":"Instruments to measure the quality of life in patients with oral mucositis undergoing oncological treatment: a systematic review of the literature","volume":"73","author":"Guti\u00e9rrez-Vargas","year":"2016","journal-title":"Bol Med Hosp Infant Mex"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0440","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00520-007-0318-8","article-title":"Chemotherapy-induced dermatological toxicity: Frequencies and impact on quality of life in women\u2019s cancers. Results of a prospective study","volume":"16","author":"Hackbarth","year":"2008","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0445","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00520-010-0851-8","article-title":"Skin care management in cancer patients: an evaluation of quality of life and tolerability","volume":"19","author":"Haley","year":"2011","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0450","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1359105308090932","article-title":"Women\u2019s experiences of an altered appearance during chemotherapy: an indication of cancer status","volume":"13","author":"Harcourt","year":"2008","journal-title":"J Health Psychol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0455","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0885-3924(02)00395-0","article-title":"Prevalence and treatment of menopausal symptoms among breast cancer survivors","volume":"23","author":"Harris","year":"2002","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0460","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr Drug Metab"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b9010","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamadermatol.2019.0063","article-title":"Association of antibiotic resistance with antibiotic use for epidermal growth factor receptor inhibitor-related papulopustular eruption","volume":"155","author":"Hirotsu","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"22","key":"10.1016\/j.ijwd.2019.10.003_b0465","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO Quality of Life Working Group","volume":"33","author":"Hofheinz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0470","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jjco\/hym042","article-title":"Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer","volume":"37","author":"Hong","year":"2007","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0475","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0480","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/ijc.31269","article-title":"Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome","volume":"142","author":"Huang","year":"2018","journal-title":"Int J Cancer"},{"issue":"15S","key":"10.1016\/j.ijwd.2019.10.003_b0485","doi-asserted-by":"crossref","first-page":"16122","DOI":"10.1200\/jco.2008.26.15_suppl.16122","article-title":"Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL)","volume":"26","author":"Huggins","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0490","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1346-8138.2012.01615.x","article-title":"Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy","volume":"39","author":"Hung","year":"2012","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b0495","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2367::AID-CNCR22>3.0.CO;2-#","article-title":"Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature","volume":"88","author":"Hussain","year":"2000","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b0500","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","article-title":"Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome?","volume":"16","author":"Jacobi","year":"2005","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0505","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ced.12538","article-title":"Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis","volume":"40","author":"Jo","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"30","key":"10.1016\/j.ijwd.2019.10.003_b0510","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1200\/JCO.2007.10.8274","article-title":"Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a tamoxifen exemestane adjuvant multicenter trial substudy","volume":"25","author":"Jones","year":"2007","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ijwd.2019.10.003_b0515","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"issue":"10S","key":"10.1016\/j.ijwd.2019.10.003_b0520","article-title":"Incidence of permanent chemotherapy-induced alopecia among breast cancer patients: a five-year prospective cohort study","volume":"28","author":"Kang","year":"2017","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.ijwd.2019.10.003_b0525","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","article-title":"Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kang","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0530","first-page":"387","article-title":"The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia","volume":"30","author":"Kanis","year":"2009","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0535","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.gco.0000192996.20040.24","article-title":"Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients","volume":"18","author":"Kayl","year":"2006","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0540","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c693","article-title":"Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study","volume":"340","author":"Kelly","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0545","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0550","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10549-017-4268-7","article-title":"A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant\/adjuvant docetaxel chemotherapy","volume":"164","author":"Kim","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0555","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00520-011-1126-8","article-title":"Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy","volume":"20","author":"Kim","year":"2012","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.ijwd.2019.10.003_b0565","doi-asserted-by":"crossref","first-page":"813","DOI":"10.7326\/0003-4819-120-9-199405010-00025","article-title":"5-fluorouracil dermatitis prophylaxis with a nicotine patch","volume":"120","author":"Kingsley","year":"1994","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0570","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000446692","article-title":"Mucocutaneous ulcerations and pancytopenia due to methotrexate overdose","volume":"8","author":"Knoll","year":"2016","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0575","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study","volume":"11","author":"Kobayashi","year":"2015","journal-title":"J-STEPP. Futur Oncol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0580","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015","volume":"19","author":"Kohne","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0585","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejon.2018.12.001","article-title":"Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: a qualitative study","volume":"38","author":"Komatsu","year":"2019","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0590","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JOP.17.00038","article-title":"Management of chemotherapy-induced alopecia with scalp cooling","volume":"14","author":"Kruse","year":"2018","journal-title":"J Oncol Pract"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0595","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archdermatol.2012.3022","article-title":"Gefitinib-induced paronychia response to autologous platelet-rich plasma","volume":"148","author":"Kwon","year":"2012","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.ijwd.2019.10.003_b0600","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdw227","article-title":"A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer","volume":"27","author":"Lacouture","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"8","key":"10.1016\/j.ijwd.2019.10.003_b0605","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0610","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.ijwd.2019.10.003_b0615","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0620","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cden.2007.10.002","article-title":"Management of oral mucositis in patients who have cancer","volume":"52","author":"Lalla","year":"2008","journal-title":"Dent Clin North Am"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0625","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case\u2013control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0630","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.4143\/crt.2017.435","article-title":"The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study","volume":"50","author":"Lee","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0635","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-014-3231-0","article-title":"No effect of scalp cooling on survival among women with breast cancer","volume":"149","author":"Lemieux","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0640","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/GRF.0000000000000126","article-title":"Vulvar and vaginal atrophy: physiology, clinical presentation, and treatment considerations","volume":"58","author":"Lev-Sagie","year":"2015","journal-title":"Clin Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0645","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00520-012-1693-3","article-title":"Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand\u2013foot skin reactions","volume":"21","author":"Li","year":"2013","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ALN.0b013e3181ed098d","article-title":"Inhibitors of angiogenesis","volume":"113","author":"Libert","year":"2010","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0655","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamadermatol.2014.2455","article-title":"Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib","volume":"151","author":"Lilly","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0660","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1470-2045(08)70131-1","article-title":"Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study","volume":"9","author":"Lipov","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0665","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0670","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002800050981","article-title":"Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia","volume":"44","author":"Lopez","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9247","key":"10.1016\/j.ijwd.2019.10.003_b0675","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ijwd.2019.10.003_b0680","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1200\/JCO.2008.19.6253","article-title":"Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis","volume":"27","author":"Loprinzi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0685","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0690","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0695","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: Part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0700","first-page":"1585","article-title":"Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials","volume":"22","author":"Macedo","year":"2014","journal-title":"Support Care Cancer"},{"issue":"19","key":"10.1016\/j.ijwd.2019.10.003_b0705","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0710","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2007.10.021","article-title":"Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling","volume":"108","author":"Mangili","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0715","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40 mg\/m2) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0720","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamadermatol.2018.3465","article-title":"Evaluation of prevention interventions for taxane-induced dermatologic adverse events","volume":"154","author":"Marks","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0725","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/OPTH.S8521","article-title":"Periorbital edema secondary to imatinib mesylate","volume":"4","author":"McClelland","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b0730","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/pon.1637","article-title":"An evaluation of a computer-imaging program to prepare women for chemotherapy-related alopecia","volume":"19","author":"McGarvey","year":"2009","journal-title":"Psychooncology"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b0735","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: Practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0740","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1529-8019.2011.01435.x","article-title":"Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib","volume":"24","author":"McLellan","year":"2011","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b0745","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.ijwd.2019.10.003_b0750","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bjc.6690098","article-title":"Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity","volume":"79","author":"Milano","year":"1999","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0755","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0760","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0765","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1013027","article-title":"More on aprepitant for erlotinib-induced pruritus","volume":"364","author":"Mir","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0770","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00404-011-2181-6","article-title":"Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors","volume":"285","author":"Moegele","year":"2012","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0775","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2004.02.019","article-title":"The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma","volume":"93","author":"Molpus","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0780","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/0167482X.2016.1216963","article-title":"Factors related to the experience of menopausal symptoms in women prescribed tamoxifen","volume":"38","author":"Moon","year":"2017","journal-title":"J Psychosom Obstet Gynecol."},{"issue":"11","key":"10.1016\/j.ijwd.2019.10.003_b0785","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/bjc.2012.482","article-title":"Association of creatine kinase and skin toxicity in phase I trials of anticancer agents","volume":"107","author":"Moreno Garcia","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0790","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF01262572","article-title":"Changes in self-concept and body image during alopecia induced cancer chemotherapy","volume":"5","author":"Munstedt","year":"1997","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0795","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ijwd.2019.10.003_b0800","first-page":"e61","article-title":"The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life","volume":"11","author":"Nardone","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0805","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events, version 5.0 [Internet]. 2017 [cited 2019 July 24]. Available from: https:\/\/www.meddra.org\/."},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0810","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1188\/06.ONF.305-311","article-title":"A randomized clinical trial of a videotape intervention for women with chemotherapy-induced alopecia: a Gynecologic Oncology Group study","volume":"33","author":"Nolte","year":"2006","journal-title":"Oncol Nurs Forum"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0815","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1346-8138.2012.01632.x","article-title":"Female pattern hair loss possibly caused by tamoxifen: Androgen receptor expression in the outer root sheath in the affected area","volume":"39","author":"Nonomura","year":"2012","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0820","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2001.117426","article-title":"Female pattern hair loss","volume":"45","author":"Olsen","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0825","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaad.2004.04.008","article-title":"Evaluation and treatment of male and female pattern hair loss","volume":"52","author":"Olsen","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0830","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejon.2010.03.004","article-title":"Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer","volume":"14","author":"Ouwerkerk","year":"2010","journal-title":"Eur J Oncol Nurs"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0835","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2010.03.020","article-title":"Permanent chemotherapy-induced alopecia: a review","volume":"64","author":"Palamaras","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"9488","key":"10.1016\/j.ijwd.2019.10.003_b0840","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","article-title":"Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial","volume":"366","author":"Pandya","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijwd.2019.10.003_b0845","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0850","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamadermatol.2018.4560","article-title":"Clinical characterization of immunotherapy-related pruritus among patients seen in 2 oncodermatology clinics","volume":"155","author":"Phillips","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0855","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clcc.2013.10.001","article-title":"Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer","volume":"13","author":"Pinta","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0860","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","article-title":"Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy","volume":"16","author":"Pinto","year":"2011","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0865","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/jdv.13071","article-title":"Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients","volume":"30","author":"Piraccini","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0870","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.breast.2017.03.011","article-title":"Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis","volume":"33","author":"Poggio","year":"2017","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0875","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000226942","article-title":"Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance","volume":"48","author":"Port","year":"1991","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0880","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpainsymman.2006.07.006","article-title":"Efficacy of pregabalin in the management of cetuximab-related itch","volume":"32","author":"Porzio","year":"2006","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b9015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2133.2009.09043.x","article-title":"Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer","volume":"160","author":"Prevezas","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0885","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12916-014-0203-5","article-title":"Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis","volume":"12","author":"Qi","year":"2014","journal-title":"BMC Med"},{"issue":"15","key":"10.1016\/j.ijwd.2019.10.003_b0890","doi-asserted-by":"crossref","first-page":"E818","DOI":"10.1503\/cmaj.111309","article-title":"Hand-foot syndrome related to chemotherapy","volume":"184","author":"Qiao","year":"2012","journal-title":"Can Med Assoc J"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0895","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/IGC.0000000000000723","article-title":"Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis","volume":"26","author":"Qin","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0900","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/j.1468-3083.2012.04466.x","article-title":"The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients","volume":"27","author":"Ra","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b0905","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b0910","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/11592120-000000000-00000","article-title":"Health-related quality of life in patients with nail disorders","volume":"12","author":"Reich","year":"2011","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.ijwd.2019.10.003_b0915","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b0920","first-page":"77","article-title":"Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin","volume":"90","author":"Requena","year":"2012","journal-title":"Cutis"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b0925","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jamaoncol.2016.2680","article-title":"Oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment","volume":"2","author":"Riley","year":"2016","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.ijwd.2019.10.003_b0930","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/oxfordjournals.annonc.a058986","article-title":"Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia","volume":"5","author":"Rodriguez","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijwd.2019.10.003_b0935","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti\u2013PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0940","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1634\/theoncologist.10-3-205","article-title":"Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer","volume":"10","author":"Rose","year":"2005","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b0945","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0950","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-008-0409-1","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0955","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0738-3991(03)00040-5","article-title":"Cancer and stigma: Experience of patients with chemotherapy-induced alopecia","volume":"52","author":"Rosman","year":"2004","journal-title":"Patient Educ Couns"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0960","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/annonc\/mdt170","article-title":"Aromatase inhibitors induce \u201cmale pattern hair loss\u201d in women?","volume":"24","author":"Rossi","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0965","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","article-title":"Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies","volume":"174","author":"Rozner","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ijwd.2019.10.003_b0970","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/ijd.13906","article-title":"Pathogenesis and treatment options for chemotherapy-induced alopecia: a systematic review","volume":"57","author":"Rubio-Gonzalez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0975","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2016.21038","article-title":"Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer","volume":"317","author":"Rugo","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b0980","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b0985","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","article-title":"American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline","volume":"34","author":"Runowicz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b0990","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaad.2016.12.031","article-title":"Etiologies and management of cutaneous flushing","volume":"77","author":"Sadeghian","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b0995","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","article-title":"Alopecia with endocrine therapies in patients with cancer","volume":"18","author":"Saggar","year":"2013","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b1000","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1158\/0008-5472.SABCS-4093","article-title":"Multicenter phase II study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity for the breast cancer patients (Kinki Multidisciplinary Breast Oncology Group: KMBOG-0605)","volume":"69","author":"Sakurai","year":"2009","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.ijwd.2019.10.003_b1005","doi-asserted-by":"crossref","first-page":"18507","DOI":"10.1200\/jco.2006.24.18_suppl.18507","article-title":"Regional cooling significantly reduces liposomal doxorubicin-induced palmar-plantar erythrodysesthesias (PPE) in patients with recurrent ovarian cancer","volume":"24","author":"Sayer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ijwd.2019.10.003_b1010","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b1015","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","article-title":"A prospective randomized trial of topical pimecrolimus for cetuximab-associated acne-like eruption","volume":"61","author":"Scope","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b1020","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scott\u00e9","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijwd.2019.10.003_b1025","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand","volume":"23","author":"Scott\u00e9","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b1030","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/jdv.14612","article-title":"Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials","volume":"32","author":"Shah","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"25","key":"10.1016\/j.ijwd.2019.10.003_b1035","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMra1712502","article-title":"Cancer survivorship","volume":"379","author":"Shapiro","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b1040","doi-asserted-by":"crossref","first-page":"E442","DOI":"10.1002\/ijc.29115","article-title":"Efficacy of interventions for prevention of chemotherapy-induced alopecia:a systematic review and meta-analysis","volume":"136","author":"Shin","year":"2015","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b1045","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/annonc\/mdt541","article-title":"A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma","volume":"25","author":"Shinohara","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b1050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b1055","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","article-title":"HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome","volume":"16","author":"Sibaud","year":"2011","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b1060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b1065","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2013PD-1 and anti\u2013PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b1070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b1075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/13697137.2012.756466","article-title":"Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview","volume":"16","author":"Sinha","year":"2013","journal-title":"Climacteric"},{"issue":"15","key":"10.1016\/j.ijwd.2019.10.003_b9020","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/jama.2019.3504","article-title":"Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial","volume":"321","author":"Sio","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b1080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2000.18.2.412","article-title":"Sex differences in fluorouracil-induced stomatitis","volume":"18","author":"Sloan","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b1085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-018-4983-8","article-title":"COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer","volume":"173","author":"Smetanay","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b1090","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jdcr.2016.08.016","article-title":"Malignant intertrigo: a subset of toxic erythema of chemotherapy requiring recognition","volume":"2","author":"Smith","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b1095","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.21873\/anticanres.13549","article-title":"Panniculitis under successful targeted inhibition of the MAPK\/ERK signaling pathway in a patient with BRAF V600E-mutated spindle cell oncocytoma of the pituitary gland","volume":"39","author":"Sollfrank","year":"2019","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b1100","first-page":"680","article-title":"Oral complications of cancer therapy","volume":"16","author":"Sonis","year":"2002","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b9025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0190-9622(99)70488-3","article-title":"Grant-Kels JM. Mucocutaneous reactions to chemotherapy","volume":"40","author":"Susser","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b1105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2009.04.007","article-title":"Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer","volume":"114","author":"Tanyi","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b1110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.breast.2014.02.005","article-title":"Prevention of palmar\u2013plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92\/08)","volume":"23","author":"Templeton","year":"2014","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b1115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-018-4788-9","article-title":"A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study","volume":"171","author":"Thomas","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b1120","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-3083.2011.04324.x","article-title":"Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis","volume":"27","author":"Tomkov\u00e1","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b1125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12282-018-0879-z","article-title":"A randomized phase II study evaluating pyridoxine for the prevention of hand\u2013foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer","volume":"25","author":"Toyama","year":"2018","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ijwd.2019.10.003_b1130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.sder.2008.12.001","article-title":"Chemotherapy-induced alopecia","volume":"1","author":"Tr\u00fceb","year":"2009","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b1135","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/CAD.0b013e32835c401c","article-title":"Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma","volume":"24","author":"Tsuchiya","year":"2013","journal-title":"Anticancer Drugs"},{"issue":"19","key":"10.1016\/j.ijwd.2019.10.003_b1140","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2006.08.8344","article-title":"Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women","volume":"25","author":"Ushijima","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b1145","first-page":"142","article-title":"Factors affecting the incidence and severity of oral mucositis following hematopoietic stem cell transplantation","volume":"12","author":"Valeh","year":"2018","journal-title":"Int J Hematol Stem Cell Res"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b1150","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/0284186X.2012.658966","article-title":"Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients \u2013 results of the Dutch Scalp Cooling Registry","volume":"51","author":"van den Hurk","year":"2012","journal-title":"Acta Oncol (Madr)"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b1155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/13697137.2012.709889","article-title":"Stellate-ganglion block as a treatment for severe postmenopausal flushing","volume":"16","author":"Van Gastel","year":"2012","journal-title":"Climacteric"},{"issue":"8","key":"10.1016\/j.ijwd.2019.10.003_b1160","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(16)30067-5","article-title":"10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study","volume":"17","author":"van Maaren","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ijwd.2019.10.003_b1165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jdcr.2017.06.001","article-title":"Delayed-onset vemurafenib-induced panniculitis","volume":"3","author":"Vance","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b1170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","article-title":"Aprepitant for erlotinib-induced pruritus","volume":"363","author":"Vincenzi","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijwd.2019.10.003_b1175","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s00520-006-0031-z","article-title":"Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study","volume":"14","author":"Vokurka","year":"2006","journal-title":"Support Care Cancer"},{"issue":"20","key":"10.1016\/j.ijwd.2019.10.003_b1180","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1002\/cncr.25262","article-title":"A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients","volume":"116","author":"von Gruenigen","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b1185","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand\u2013foot syndrome: Recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"issue":"11 Suppl 5","key":"10.1016\/j.ijwd.2019.10.003_b1190","first-page":"34","article-title":"Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae","volume":"21","author":"Wagner","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.ijwd.2019.10.003_b1195","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0738-081X(93)90057-J","article-title":"The red face: flushing disorders","volume":"11","author":"Wilkin","year":"1993","journal-title":"Clin Dermatol"},{"issue":"10","key":"10.1016\/j.ijwd.2019.10.003_b1200","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00520-007-0232-0","article-title":"Nail changes due to docetaxel\u2014a neglected side effect and nuisance for the patient","volume":"15","author":"Winther","year":"2007","journal-title":"Support Care Cancer"},{"issue":"35","key":"10.1016\/j.ijwd.2019.10.003_b1205","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","article-title":"Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5","volume":"28","author":"Wolf","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b1210","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/annonc\/mdp278","article-title":"Travel warning with capecitabine","volume":"20","author":"Wong","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ijwd.2019.10.003_b1215","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.5021\/ad.2011.23.S3.S350","article-title":"A case of cicatricial alopecia associated with erlotinib","volume":"23","author":"Yang","year":"2011","journal-title":"Ann Dermatol"},{"issue":"11","key":"10.1016\/j.ijwd.2019.10.003_b1220","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","article-title":"Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome","volume":"3","author":"Yap","year":"2017","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ijwd.2019.10.003_b1225","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12282-009-0171-3","article-title":"Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer","volume":"17","author":"Yoshimoto","year":"2010","journal-title":"Breast Cancer"},{"issue":"7","key":"10.1016\/j.ijwd.2019.10.003_b1230","doi-asserted-by":"crossref","first-page":"15508","DOI":"10.1111\/jdv.15508","article-title":"Nail changes due to chemotherapy: a prospective observational study of 129 patients","volume":"33","author":"Zawar","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ijwd.2019.10.003_b1235","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","article-title":"The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study","volume":"137","author":"Zhang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijwd.2019.10.003_b1240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0254-6272(14)60047-9","article-title":"Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome","volume":"34","author":"Zhao","year":"2014","journal-title":"J Tradit Chinese Med"},{"issue":"3","key":"10.1016\/j.ijwd.2019.10.003_b1245","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"}],"container-title":["International Journal of Women's Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647519301108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352647519301108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T22:52:32Z","timestamp":1664837552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352647519301108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":252,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2352647519301108"],"URL":"https:\/\/doi.org\/10.1016\/j.ijwd.2019.10.003","relation":{},"ISSN":["2352-6475"],"issn-type":[{"value":"2352-6475","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic conditions in women receiving systemic cancer therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Women's Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijwd.2019.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.","name":"copyright","label":"Copyright"}]}}